UCMA Antibody | 5211

UCMA Antibody | 5211 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human, Mouse

Homology: Predicted species reactivity based on immunogen sequence: Rat: (81%)

Immunogen: UCMA antibody was raised against a 16 amino acid synthetic peptide near the carboxy terminus of human UCMA.
The immunogen is located within the last 50 amino acids of UCMA.

Research Area: Stem Cell

Tested Application: E, WB

Application: UCMA antibody can be used for detection of UCMA by Western blot at 2.5 - 5 μg/mL.
Antibody validated: Western Blot in human samples. All other applications and species not yet tested.

Specificiy: N/A

Positive Control 1: Cat. No. 1214 - SW1353 Cell Lysate

Positive Control 2: N/A

Positive Control 3: N/A

Positive Control 4: N/A

Positive Control 5: N/A

Positive Control 6: N/A

Molecular Weight: Predicted: 15 kDa
Observed: 19 kDa

Validation: N/A

Isoform: N/A

Purification: UCMA Antibody is affinity chromatography purified via peptide column.

Clonality: Polyclonal

Clone: N/A

Isotype: IgG

Conjugate: Unconjugated

Physical State: Liquid

Buffer: UCMA Antibody is supplied in PBS containing 0.02% sodium azide.

Concentration: 1 mg/mL

Storage Condition: UCMA antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Alternate Name: UCMA Antibody: GRP, C10orf49, Unique cartilage matrix-associated protein, Gla-rich protein, Ucma-C

User Note: Optimal dilutions for each application to be determined by the researcher.

BACKGROUND: UCMA Antibody: UCMA is a secreted cartilage-specific protein that was discovered in a screen for differentially expressed genes in retinoic acid-treated mouse chondrocytes. It was also identified in a human chondrocyte EST screen for candidate genes of skeletal dysplasias. UCMA expression is thought to parallel that of collagen II with its expression decreasing with maturation chrondrocytes mature. UCMA is processed by a furin-like protease into two fragments, an amino-terminal fragment and a carboxy-terminal fragment (UCMA-C) . Application of recombinant UCMA-C to primary osteoblasts, mesenchymal stem cells, and MC3T3-E1 pre-osteoblasts interferes with their osteogenic differentiation, but does not affect expression of chondrocyte-specific genes or chondrocyte proliferation, suggesting that UCMA may be involved in the negative control of osteogenic differentiation of osteochondrogenic precursor cells. At least two isoforms of UCMA are known to exist.